Baek Jung-hyun, director of the Korea Children's Hospital, presents the abstract of mycoplasma research paper
Nov 04, 2024
Our Children's Medical Foundation Woori Children's Hospital (Chairman Jung Sung-kwan, Hospital Director Baek Jung-hyun), a hospital specializing in children and adolescents, held at Grand Walkerhill Seoul on October 24th and 25th at the 74th Fall Conference of the Korean Association of Pediatrics & Childhood Sciences. Comparing Macrolide Sensitive Mycoplasma Pneumonia (MSMP) and Macrolide Resistant Mycoplasma Pneumonia (MRMP) during the 2023-2024 Mycoplasma Pand.
Mycoplasma pneumoniae is the most common cause of lower respiratory infections and community-acquired pneumonia occurring in children and adolescents during school years. It is popular every four to seven years, and it is popular in Korea every four years, and the trend has recently been observed in 2011, 2015, 2019, and 2023-2024. The Korea Centers for Disease Control and Prevention issued a mycoplasma pneumonia epidemic warning from June 24 as the number of weekly hospitalized patients with mycoplasma pneumonia has continued to be more than 250 for two consecutive weeks since May 4 this year.
In addition, the Korea Centers for Disease Control and Prevention and the Korean Academy of Pediatric Allergy and Respiratory Diseases recommend that if there is no clinical improvement in macrolide due to the increased resistance rate of mycoplasma pneumonia treatment, the age-restricted drug tetracycline (doxycycline) or quinolone (lebofloxacin).
Accordingly, Woori Children's Hospital presented the results of data analysis through a chart review of 358 patients diagnosed with mycoplasma pneumonia from May 2023 to May 2024, during the epidemic of mycoplasma pneumonia.
The study identified 215 (60%) of a total of 358 patients as macrolide refractory mycoplasma pneumoniae (MRMP), with resistant variants predominantly A2063G.
If macrolide treatment did not respond, treatment was performed with tetracycline (doxycycline) or quinolone (rebofloxacin). As a result, there was no statistical difference between the macrolide-insensitive mycoplasma pneumonia (MRMP) group and the macrolide-sensitive mycoplasma pneumonia (MSMP) group, with a mean hospitalization period of 6.01±1.72 days vs. 6.23±1.80 days (p-value of 0.508) and a mean fever period of 5.29±2.64 days vs. 4.89±2.47 days (p-value of 0.424).
Hospital Director Baek Jeong-hyun said, "During the mycoplasma epidemic, pediatricians have a higher risk of disease burden for the macrolide-insensitive mycoplasma pneumoniae (MRMP) group. However, the study found that in the absence of response to macrolides, fever and hospital stay can be maintained similar to those of the macrolide sensitive mycoplasma pneumonia (MSMP) group through tetracycline (doxycycline) or quinolone (rebofloxacin) administration.
Mycoplasma pneumoniae is the most common cause of lower respiratory infections and community-acquired pneumonia occurring in children and adolescents during school years. It is popular every four to seven years, and it is popular in Korea every four years, and the trend has recently been observed in 2011, 2015, 2019, and 2023-2024. The Korea Centers for Disease Control and Prevention issued a mycoplasma pneumonia epidemic warning from June 24 as the number of weekly hospitalized patients with mycoplasma pneumonia has continued to be more than 250 for two consecutive weeks since May 4 this year.
In addition, the Korea Centers for Disease Control and Prevention and the Korean Academy of Pediatric Allergy and Respiratory Diseases recommend that if there is no clinical improvement in macrolide due to the increased resistance rate of mycoplasma pneumonia treatment, the age-restricted drug tetracycline (doxycycline) or quinolone (lebofloxacin).
Accordingly, Woori Children's Hospital presented the results of data analysis through a chart review of 358 patients diagnosed with mycoplasma pneumonia from May 2023 to May 2024, during the epidemic of mycoplasma pneumonia.
The study identified 215 (60%) of a total of 358 patients as macrolide refractory mycoplasma pneumoniae (MRMP), with resistant variants predominantly A2063G.
If macrolide treatment did not respond, treatment was performed with tetracycline (doxycycline) or quinolone (rebofloxacin). As a result, there was no statistical difference between the macrolide-insensitive mycoplasma pneumonia (MRMP) group and the macrolide-sensitive mycoplasma pneumonia (MSMP) group, with a mean hospitalization period of 6.01±1.72 days vs. 6.23±1.80 days (p-value of 0.508) and a mean fever period of 5.29±2.64 days vs. 4.89±2.47 days (p-value of 0.424).
Hospital Director Baek Jeong-hyun said, "During the mycoplasma epidemic, pediatricians have a higher risk of disease burden for the macrolide-insensitive mycoplasma pneumoniae (MRMP) group. However, the study found that in the absence of response to macrolides, fever and hospital stay can be maintained similar to those of the macrolide sensitive mycoplasma pneumonia (MSMP) group through tetracycline (doxycycline) or quinolone (rebofloxacin) administration.
|
bellho@sportschosun.com
